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Abstract
Thrombomodulin (TM) is a cell surface glycoprotein which is widely expressed in a variety of cell types. It is a
cofactor for thrombin binding that mediates protein C activation and inhibits thrombin activity. In addition to its
anticoagulant activity, recent evidence has revealed that TM, especially its lectin-like domain, has potent anti-
inflammatory function through a variety of molecular mechanisms. The lectin-like domain of TM plays an important
role in suppressing inflammation independent of the TM anticoagulant activity. This article makes an extensive
review of the role of TM in inflammation. The molecular targets of TM lectin-like domain have also been
elucidated. Recombinant TM protein, especially the TM lectin-like domain may play a promising role in the
management of sepsis, glomerulonephritis and arthritis. These data demonstrated the potential therapeutic role of
TM in the treatment of inflammatory diseases.
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Introduction
Thrombomodulin (TM) is a cell surface-expressed
transmembrane glycoprotein which is originally identi-
fied on vascular endothelium. The cDNA sequence of
TM has been determined with the cloning and sequen-
cing of the human TM gene [1]. The mature human
TM protein and its secondary structure have also been
resolved [2]. TM protein has 557 amino acids, and its
structure consists of 5 domains including a highly
charged N-terminal lectin-like domain (D1), a domain
with six epidermal growth factor (EGF)-like structures
(D2), a serine and threonine-rich domain (D3), a trans-
membrane domain (D4) and a cytoplasmic domain (D5)
[2] (Figure 1). TM on vascular endothelial cells is an
important molecule in human natural anticoagulation
system. After a stimulus, blood coagulation cascade
amplifies and produces a high level of thrombin, the key
effector of coagulation cascade. Natural anticoagulant
mechanisms are activated to prevent excessive thrombin
generation. TM acts as a thrombin receptor on the sur-
face of vascular endothelial cells. The binding of TM to
thrombin significantly decreases the thrombin’s effect in
conversion of fibrinogen to fibrin, and activation of coa-
gulation factor V, VIII and platelet. Thrombin-TM com-
plex catalyzes the activation of protein C about 1000
times faster than free thrombin. Activated protein C
proteolytically inactivates the coagulation cofactor Va
and VIIIa, thereby inhibiting the amplification of the
coagulation system [3-5]. The importance of TM in nat-
ural anticoagulant system was demonstrated by the
observation that transgenic mice with endothelium-spe-
cific loss of TM developed severe spontaneous thrombo-
sis in the arterial and venous circulation, and inevitably
led to the death of animal [6]. In addition to endothe-
lium, TM is expressed in smooth muscle cell [7], plate-
let [8], monocyte [9], and cardiomyocyte [10]. TM is
also expressed in some cancer cells and influences the
growth and metastasis of cancer [11,12]. The presence
of TM in these cells implies that the biological function
of TM is not limited to anticoagulation [13]. Function-
ally, the region including the fourth, fifth, and sixth
EGF-like structures of the second domain of TM
(TMD2) is responsible for thrombin binding and protein
C activation [14]. The lectin-like domain (the first
domain of TM, TMD1) plays no role in the TM’s antic-
oagulant activity. Although initial studies consider TM
to be an anticoagulant, recent studies have revealed that
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TM and inflammation
Initially, TM is considered to have indirect anti-inflam-
matory activity and works mainly through its effect in
producing activated protein C and suppressing thrombin
activity. First, thrombin-TM complex produces a large
amount of activated protein C which has a variety of
anti-inflammatory activities. Activated protein C pre-
vents inflammation-induced vascular permeability
[15,16], suppresses inflammatory cytokine elevation in
sepsis [17], inhibits leukocyte adhesion and decreases
leukocyte chemotaxis [18]. After binding to endothelial
protein C receptor (EPCR), activated protein C activates
the protease-activated receptor 1 (PAR-1) and its down-
stream sphingosine-1 phosphate receptor 1 signaling
pathway to execute the anti-inflammatory effects [15].
Second, TM decreases the pro-inflammatory effects of
thrombin when TM binds to thrombin. Thrombin is a
potent stimulus of inflammatory reaction. It disrupts the
endothelial cell junction and increases tumor necrosis
factor alpha production from monocytes [19]. It facili-
tates the recruitment of circulating monocytes by
increasing endothelial expression of monocyte chemoat-
tractant protein-1 (MCP-1), intercellular adhesion mole-
cule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) [20,21]. The thrombin signaling pathway is
also via PAR-1 activation, but its downstream effector is
coupled to the sphingosine-1 phosphate receptor 3. TM
inhibits the interaction of thrombin with PAR-1, and
decreasing thrombin’s all pro-inflammatory effects. So
TM plays a pivotal role in regulating the balance
between activated protein C/EPCR/PAR1/sphingosine-1
phosphate receptor 1 and thrombin/PAR1/sphingosine-1
phosphate receptor 3 pathways during inflammation
[22]. Through its thrombin inhibitory effect, infusion of
recombinant D2 plus D3 of TM (rTMD23) protein
could significantly reduce inflammation and decrease
atherosclerosis formation in apolipoprotein E-deficient
mice [23]. Third, thrombin-TM complex activates
thrombin activatable fibrinolysis inhibitor (TAFI), also
known as procarboxypeptidase R, a procarboxypeptidase
that degrades several pro-inflammatory mediators such
as bradykinin and complement factors C3a and C5a.
Complement system is one of the important effectors in
human immunity. Excessive activation of the comple-
ment system leads to several inflammatory diseases.
Similar to the activation of protein C, TAFI is activated
by the thrombin-TM complex with a catalytic efficiency
of 1000-fold better than free thrombin alone. TAFI
cleaves carboxyl terminal arginines of complement fac-
tors and bradykinin, inactivating their biological activ-
ities and downregulates the associated inflammatory
reaction [24]. Although TMD1 does not involve in
thrombin binding and has no effect in protein C activa-
tion, recent studies showed that TMD1 itself has direct
anti-inflammatory activity.
TMD1 structure
TMD1 consists of the first 1-155 amino acid residues in
the N-terminal region of TM. There is a homology
between TMD1 and the C-type lectin family. Originally,
the C-type lectin was used to describe a group of Ca
2
+-dependent carbohydrate-binding (lectin) proteins. Sub-
sequent studies demonstrated that the carbohydrate
binding sites of C-type lectin usually exist in a compact
protein region that became known as the C-type lectin
domain and can be present in many other proteins. Pre-
vious study showed that TMD1 folds into a globular
structure that consists of two alpha helices and six beta-
strands forming two antiparallel beta-sheets [25,26].
Although TMD1 displays the essential features of the C-
type lectin modules, it lacks traditional calcium binding
site. Electron microscopy study demonstrated that TM
is an elongated molecule about 20 nm long and TMD1
is a 5 nm nodular structure at its end [26]. These struc-
ture studies show that TM is a single chain membrane
protein with TMD1 being furthest away from the
plasma membrane. The location of TMD1 provides an
ideal site for effective interaction with other molecules
or cells. Interestingly, the structure and location of
TMD1 in TM protein are similar to a group of protein
currently known as C-type lectin receptors [27]. These
receptors are transmembrane proteins bearing a C-type
lectin domain with or without intracellular signal motifs.
Some of the C-type lectin receptors may bind to
Figure 1 Schematic presentation of structural domains of TM
with corresponding sequence of amino acid. EGF, epidermal
growth factor. Ser, serine; Thr, threonine; D1, domain 1; D2, domain
2; D3, domain 3; D4, domain 4; D5, domain 5.
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duce signaling pathways into the cell to elicit inflamma-
tory responses and play a critical role in host defense
[27].
Anti-inflammatory effect of TMD1
The anti-inflammatory effect of TMD1 was first demon-
s t r a t e db yo b s e r v i n gt h a tt h et r a n s g e n i cm i c ew i t h
deleted TMD1 of TM protein (TM
LeD/LeD) elaborated
more inflammatory cytokines, including tumor necrosis
factor and interleukin-1, and presented stronger inflam-
matory reaction after lipopolysaccharide (LPS) stimula-
tion [28]. The transgenic mice have more leukocytes
accumulation in the lungs after inhalation of gram-nega-
tive bacteria and increased mortality in endotoxin-
induced sepsis. In vitro study showed that, in endothelial
cells isolated from the TM
LeD/LeD mice, there was
enhanced expression of ICAM-1 and VCAM-1, and
increased neutrophils adhesion to endothelium [28].
Recombinant TMD1 (rTMD1) reduces the neutrophils
adhesion to endothelium and suppresses activation of
nuclear factor kappa B and mitogen-activated protein
kinase pathways. TMD1 deletion does not interfere with
the activation of protein C, indicating the direct anti-
inflammatory effect of TMD1. The other clue showing
TMD1 might be involved in inflammation comes from
the observation that TMD1 plays an important role in
maintaining cell-cell adhesion [29]. The A2058 mela-
noma cells transfected with wild type TM clustered clo-
sely together with strong cell-cell adhesion. However, in
A2058 cells transfected with TMD1-deleted TM, the
cells were dispersed as single cells in nonconfluent cell
densities as parental A2058 cells. Antibody against lec-
tin-like domain of TM was able to block cell-cell con-
tacts and inhibited close clustering morphology in the
wild type TM-transfected cells [29]. Taken together,
these results provide a possibility that TM may maintain
the integrity of endothelial junctions, thereby keeping a
quiescent state of blood vessels [30].
The definite molecular mechanisms mediating the
anti-inflammatory effect of TMD1 has been elucidated
recently and at least 2 binding targets of TMD1 have
been identified. The first one is high mobility group box
1 (HMGB1) protein. HMGB1 is released from necrotic
cells [31] or secreted by inflammatory cells such as acti-
vated monocytes [32] after cytokine stimulation. It is a
potent pro-inflammatory mediator and, recently,
becomes a target of treatment for inflammation [33].
HMGB1 binds to its endothelial cell surface receptor,
receptor for advanced glycation end products (RAGE) or
toll-like receptors to trigger the activation of down-
stream pro-inflammatory pathway and tissue damage.
TM binds to HMGB1 protein through its D1 domain
and interferes the binding of HMGB1 to RAGE [34].
The prevention of HMGB1 to bind RAGE by TMD1
decreases the pro-inflammatory effect of HMGB1 and
subsequent inflammation (Figure 2). Later study shows
that, after binding to TMD1, HMGB1 can be effectively
degraded by thrombin-TM complex to a less pro-
inflammatory form and the inflammatory reaction is
further down-regulated [35].
Another binding target of TMD1 is the carbohydrate
Lewis Y antigen in LPS on gram-negative bacteria [36].
L P Si sam a j o rc e l lw a l lc o m p o n e n to fg r a m - n e g a t i v e
bacteria and acts as a major endotoxin that elicits strong
inflammatory responses during infection. LPS interacts
with CD14 and toll-like receptor on the cell surface and
transduces signals from the cell membrane into the
cytosol, starting the downstream inflammatory signaling
pathway [37]. Previous study demonstrated that LPS of
Helicobacter pylori contains sequences related to Lewis
X and Lewis Y antigens and interacts with selectins [38].
Soluble TMD1 or rTMD1 could directly bind to LPS,
block the interaction of LPS with CD14 and reduce the
subsequent LPS-induced inflammatory reaction by sup-
pressing the activation of mitogen-activated protein
kinase and nuclear factor kappa B signaling pathways.
The release of pro-inflammatory cytokines and expres-
sion of inducible nitric oxide synthase were also
decreased [36]. The Lewis Y antigen in LPS is the speci-
fic molecular target that is bound by TMD1 (Figure 3).
By binding to the Lewis Y antigen, rTMD1 can specifi-
cally induce the agglutination of Klebsiella pneumoniae
in the presence of Ca
+2 and enhance the phagocytosis of
the bacteria by macrophages [36]. These phenomena
indicated that TMD1 may function as a natural opsonin
for innate immunity against gram-negative bacteria.
Finally, the anti-inflammatory activity of TMD1 may
also relate to its ability to suppress the activation of
complement system directly. Increased complement
activation was found in the TM
LeD/LeD mice [39]. TM
downregulates the alternative pathway of complement
activation by directly enhancing the endogenous com-
plement inhibitors, complement factor I and H, to inac-
tivate C3b [40]. Several TM genetic mutations in the
TMD1 causing defects in TM binding of complement
factor H and C3b were observed in patients with atypi-
cal hemolytic-uremic syndrome, a disease with comple-
ment overactivation [40]. However, the definite
mechanism of molecular interaction of TM with com-
plement system needs further investigation.
Recombinant TM for inflammatory diseases
TM and sepsis
All the previous data demonstrate that the anti-inflam-
matory activity of recombinant TM protein, especially
the rTMD1, has therapeutic potential in inflammatory
diseases. Sepsis is a clinical syndrome caused by
Li et al. Journal of Biomedical Science 2012, 19:34
http://www.jbiomedsci.com/content/19/1/34
Page 3 of 8bacterial or viral infection-induced systemic inflamma-
tory response [41]. Endotoxin or LPS of the infectious
pathogen is responsible for pathophysiological events
occurring during sepsis and leads to systemic inflamma-
tion and coagulation. Disseminated intravascular coagu-
lation (DIC), which is manifested as coagulation
abnormalities, pulmonary vascular permeability dysfunc-
tion, and acute respiratory distress syndrome (ARDS)
are common complications of sepsis and lead to high
mortality [42]. Recombinant TM has been investigated
in several animal models of sepsis. In rats, pretreatment
of recombinant TM protein containing all the extracel-
lular domains (rTMD123) significantly reduced the mor-
tality of LPS-induced sepsis [43]. rTMD123 treatment
decreased inflammatory cells infiltration in lung and
liver. It decreased the elevation of tumor necrosis fac-
tor-alpha, interleukin-6 and HMGB1. Furthermore, in
vitro study showed that rTMD123 administration inhib-
ited the nuclear factor-kappa B activation by blocking I
kappa B phosphorylation in macrophages [43]. In mouse
sepsis model, mice receiving rTMD1 injection have sig-
nificantly less tumor necrosis factor-alpha elevation and
inflammatory cells infiltration in lung tissue. rTMD1
treatment decreased sepsis mortality caused by LPS and
gram-negative bacteria [36]. All the data suggest that
recombinant TM protein can be used to treat inflamma-
tion in sepsis. Saito et al. used rTMD123 to perform a
phase III clinical trial in patients with DIC caused by
hematological malignancy or infection [44]. They com-
pared the DIC resolution rate between the patients
received rTMD123 and heparin. rTMD123 treatment
resulted in a better DIC resolution than heparin. The
decrease of plasma thrombin-antithrombin complex and
D-dimer levels were significantly greater in rTMD123
Figure 2 TM suppresses HMGB1-mediated inflammation. HMGB1 mediated-pro-inflammatory pathways are inhibited by TM through two
mechanisms. First, Soluble TMD1 sequesters HMGB1, and results in decreasing its binding to RAGE, thereby suppressing the inflammatory
response. Second, thrombin-TM complex cleaves HMGB1, resulting in generation of inactive HMGB1 fragment. HMGB1, high mobility group B1;
RAGE, receptor for advanced glycation end products; TMD1, TM domain 1.
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b e t w e e nt h e2g r o u p s[ 4 4 ] .U pt on o w ,t h e r eh a sn o
data available on administration of rTMD1 to patients
with sepsis. Because rTMD1 has no effect in binding
thrombin and activating protein C, the bleeding risk
after injection of rTMD1 should be less than rTMD123.
Further clinical trials are necessary to evaluate the
rTMD1 effect in patients with sepsis.
TM and glomerulonephritis
Glomerulonephritis is one of the major causes of renal
failure. The disease results from glomeruli injury caused
by a variable of insults, such as infection, immunological
disorders and vasculitis, and the resultant inflammation
and coagulation lead to glomeruli damage and renal fail-
ure. In a rat model of glomerulonephritis induced by
simultaneous administration of LPS and anti-glomerular
basement membrane antibody, Ikeguchi et al. found
rTMD123 injection could decrease the thrombus
deposition and inflammatory cells infiltration in the
glomeruli, salvage the acute renal dysfunction and
reduce the mortality of the animals [45]. The comple-
ment activation and glomerular C3 deposition are major
manifestations in this animal glomerulonephritis model.
They further found the plasma level of TAFI was greatly
increased after TM injection, and TAFI inhibitor signifi-
cantly diminished the inhibitory effect of TM on leuko-
cyte infiltration [45].
Acute kidney injury resulting from renal ischemia is
another important cause of renal failure. Inflammation,
renal tubular epithelial cell dysfunction and apoptosis
play important roles in the pathogenesis of ischemic
renal injury. Ozaki et al. created an ischemia/reperfusion
renal injury model in rats by performing right nephrect-
omy and left renal artery clamping. Intrarenal injection
of rTMD123 could preserve a better renal function after
ischemia/reperfusion renal injury [46]. The severity of
renal tubular damage was evaluated by the extent of
tubular dilatation, degeneration, and cast formation.
Compared with saline injection, rTMD123 could
decrease renal tubular damage and inflammatory cells
infiltration. Furthermore, in vivo study showed that
rTMD123 treatment reduced the apoptosis of renal tub-
ular epithelial cells after ischemia/reperfusion renal
injury; while in vitro study showed rTMD123 treatment
could reduce hydrogen peroxide-induced endothelial
cells apoptosis [46]. The protective effect of TM in
ischemic renal injury was reconfirmed in another animal
model. Sharfuddin et al. performed suprarenal aorta
clamping to reduce 90% aortic flow for 60 min and
induced ischemia/reperfusion renal injury [47]. In this
model, pretreatment of recombinant TM protein con-
taining D1 and D2 (rTMD12) significantly reduced the
severity of renal tubular damage, inflammatory cells
infiltration and mortality in rats. Interestingly, in this
study, a point mutation in the TMD2 region which is
responsible for protein C activation was generated. They
found the mutant rTMD12 has no ability to activate
protein C but still has the same renoprotective effect as
the wild type TM indicating the importance of TMD1
anti-inflammatory effect [47]. Our study demonstrated
LPS injection alone could induce severe glomerulone-
phritis in mice. Mice receiving only rTMD1 injection
had less extent of glomerulonephritis and better renal
function than the control mice [36]. These data recon-
firmed that the TMD1 has direct anti-inflammatory
function that is independent of activated protein C
effect. In addition, activation of epidermal growth factor
receptor (EGFR) was demonstrated in glomerular dis-
ease, especially rapidly progressive glomerulonephritis
[48,49]. Our recent study showed that rTMD1 interfere
EGFR signaling through interaction with LeY, thereby
suppressing EGF-mediated angiogenesis and tumor
growth [50]. Taken together, rTMD1 is promising in the
Figure 3 TMD1 interferes with LPS-mediated inflammation.
Soluble TMD1 binds to Lewis Y antigen on the LPS, thereby
preventing engagement of LPS, CD14, and TLR4, resulting in
reduced activity of NFB and mitogen activated kinase/ERK
pathways. LeY, Lewis Y antigen; TLR4, toll-like receptor 4; NFB,
nuclear factor B; ERK, extracellular signal regulated protein kinases.
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glomerulonephritis.
TM and arthritis
Rheumatoid arthritis is a chronic inflammatory autoim-
mune disease of joints. Pathological examination
revealed chronic synovial inflammation and progressive
destruction of the affected joints. The major inflamma-
tory cell type in synovial tissue that is responsible for
pro-inflammatory cytokines production is macrophage.
Tumor necrosis factor-alpha and interleukin-1 from
macrophage play a pivotal role in the pathogenesis and
inflammatory progression of rheumatoid arthritis. Pre-
vious studies showed that the soluble TM level is
increased in the urine and joint fluid from the patients
with rheumatoid arthritis [51,52] and TM is synthesized
and expressed by the synovial lining cells [9,52]. These
data implied that TM might play important role in the
pathogenesis of rheumatoid arthritis. TM
LeD/LeD mice
developed more severe inflammatory arthritis in an anti-
collagen antibody-induced arthritis model [39]. The
mice developed more significant swelling in the paws
and inflammatory cells infiltration in the synovial tissues
than the wild type counterparts. Treatment of the mice
with rTMD1 significantly improved the arthritis severity,
decreased the thickness of synovial lining, suppressed
the macrophage infiltration in synovial tissue, and
reduced the HMGB1 expression in these macrophages
[39]. There was increased complement deposition in the
joint. Further in vitro studies showed that rTMD1 could
suppress the complement pathways activation [39]. In
addition, our current study suggested that rTMD1 may
protect against arthritis progression through sequestra-
tion of LeY, which was increased in synovial fluid from
patients with rheumatoid arthritis [53]. These data
implied that rTMD1 may be used as a therapeutic agent
in the inflammatory arthritis.
Conclusion
Inflammation is a complex pathological process that is
induced by various mediators secreted from inflamma-
tory cells. Coagulation cascade is one of the systems
that involved in the inflammatory process. Although tra-
ditionally known as an anticoagulant protein, TM has
been identified to play an important role in modulating
inflammation through several indirect and direct path-
ways [54]. The molecular switch of TM from anticoagu-
lation to regulation of inflammation may be triggered by
inflammatory stimulation thus exposing its lectin-like
domain for further interaction and signal transduction
[55]. The direct anti-inflammatory effect of TMD1 has
been found recently and its molecular targets have also
been elucidated. The use of recombinant TM protein to
treat inflammatory diseases in human and animal stu-
dies has demonstrated TM to be a new potential
therapy for patients with sepsis, glomerulonephritis and
arthritis. Because TMD1 does not participate in anticoa-
gulation, rTMD1 should not have the bleeding side
effect. It is promising in the treatment of inflammatory
diseases. Further clinical trials will be necessary to eluci-
date its safety and clinical usefulness.
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